A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma

British Journal of Haematology

Volumn 97, Issue 1, 1997, Pages 153-160

  Raje, Noopur ^a   Powles, Ray ^a,b   Kulkarni, Samar ^a   Milan, Sarah ^a   Middleton, Gary ^a   Singhal, Seema ^a   Mehta, Jayesh ^a   Millar, Barbara ^a   Viner, Christine ^a   Raymond, Julian ^a   Treleaven, Jennifer ^a   Cunningham, David ^a   Gore, Martin ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

autografting; induction chemotherapy; infusional; myeloma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; METHYLPREDNISOLONE; VERAPAMIL; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOGRAFT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL;

EID: 8244254365     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.d01-2122.x     Document Type: Article

References (25)

1. Alexanian, R. & Dimopoulos, M. (1994) The treatment of multiple myeloma. New England Journal of Medicine, 330, 484-489.
2. Alexanian, R., Yap, B.S. & Bodey, G.P. (1983) Prednisone pulse therapy for refractory myeloma. Blood, 62, 572-577.
3. Barlogie, B., Anderson, K., Berenson, J., Crowley, J., Cunningham, D., Gertz, M., Henon, P., Horowitz, M., Jagannath, S., Powles, R., Reece, D., Reiffers, J., Salmon, S., Tricot, G. & Vesole, D. (1995) Transplants for multiple myeloma. Bone Marrow Transplantation, 16, S234-S239.
4. Barlogie, B., Jagannath, S., Vesole, D., Miller, L., Cheson, B., Bracy, D. & Tricot, G. (1994) Total therapy (TT) for 202 newly diagnosed patients with multiple myeloma. Blood, 84, 10 (abstract 386).
5. Barlogie, B., Smith, L. & Alexanian, R. (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. New England Journal of Medicine, 310, 1353-1356.
6. Bell, J.B.G., Millar, B.C., Montes-Borinaga, A., Joffe, J.K., Cunningham, D., Mansi, J., Treleaven, J., Viner, C. & McElwain, T.J. (1990) Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone. Haematology Oncology, 8, 347-353.
7. Cooper, M.R., Dear, K., McIntyre, O.R., Ozer, H., Ellerton, J., Canellos, C., Bernhardt, B., Duggan, D., Faragher, D. & Schiffer, C. (1993) A randomized clinical trial comparing melphalan/prednisolone with or without interferon alpha-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 1, 155-160.
8. Cunningham, D., Powles, R., Malpas, J., Milan, S., Meldrum, M., Viner, C., Montes, A., Hickish, T. Nicolson, M., Johnson, P., Mansi, J., Treleaven, J., Raymond, J. & Gore, M.E. (1993) A randomised trial of maintenance therapy with Intron-A following high dose melphalan and ABMT in myeloma. American Society of Clinical Oncology Abstracts, 12, 364.
9. Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleaven, J., Viner, C., Malpas, J., Slevin, M., Findlay, M., Raymond, J. & Gore, M.E. (1994) High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. Journal of Clinical Oncology, 12, 759-763.
10. Drewinko, B., Alexanian, R., Boyer, H., Barlogie, B. & Rubinow, S.I. (1981) The growth fraction of human myeloma cells. Blood, 7, 333-338.
11. Durie, B.G.M. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer, 36, 842-854.
12. Porgesson, G.V., Selby, P., Lakhani, S., Zulian, G., Viner, C., Maitland, J. & McElwain, T.J. (1988) Infused vincristine and adriamycin with high dose methyl prednisolone (VAMP) in advanced previously treated multiple myeloma patients. British Journal of Cancer, 58, 469-473.
13. Gore, M.E., Selby, P.J., Millar, B., Maitland, J. & McElwain, T.J. (1988) The use of verapamil to overcome drug resistance in myeloma. (Abstract). Proceedings of the American Society of Clinical Oncology, 7, 228.
14. Gore, M.E., Selby, P.J., Viner, C., Clark, P.I., Meldrum, M., Millar, B., Bell, J., Maitland, J.A., Milan, S., Judson, I.R., Zuiable, A., Tillyer, C., Slevin, M., Malpas, J.S. & McElwain, T.J. (1989) Intensive treatment for multiple myeloma and criteria for complete remission. Lancet, ii, 879-882.
15. Kaplan, E.L. & Meier, P. (1958) Non-parametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
16. MacLennan, I.C.M., Chapman, C., Dunn, J. & Kelly, K. (1992) Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet, 239, 200-205.
17. Maitland, J.A., Millar, B.C., Bell, J.B.G., Montes, A., Treleaven, J., Gore, M.E. & McElwain, T.J. (1990) Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response. British Journal of Cancer, 61, 429-433.
18. McElwain, T.J. & Powles, R.L. (1983) High dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet, ii, 822-824.
19. Millar, B.C., Bell, J.B.G., Maitland, J.A., Zuiable, A., Gore, M.E., Selby, P.J. & McElwain, T.J. (1989) In vitro studies of ways to overcome drug resistance to VAMP-high-dose melphalan in the treatment of multiple myeloma. British Journal of Haematology, 71, 213-222.
20. Peto, R. & Peto, J. (1972) Asymptomatically efficient invariant procedures. Journal of the Royal Statistical Society, 135, 185-206.
21. Powles, R.L., Raje, N.S., Cunningham, D., Malpas, J., Milan, S., Horton, C., Mehta, J., Singhal, S., Viner, C. & Treleaven, J. (1995) Maintenance therapy for remission in myeloma with Intron A following either an autologous bone marrow transplantation or peripheral stem cell rescue. Stem Cells, 13, 114-117.
22. Salmon, S.E., Crowley, J.J., Grogan, T.M., Finley, P., Pugh, R.P. & Barlogie, B. (1994) Combination chemotherapy, glucocorticoids and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology, 12, 2405-2414.
23. Samson, D., Gammara, E., Newland, A., Van de Pette, J., Kearney, J., McCarthy, D., Joyner, M., Aston, L., Mitchell, T., Hamon, M. & Evans, M. (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet, ii, 882-885.
24. Singhal, S., Powles, R., Milan, S., Raje, N., Viner, C., Treleaven, J., Raymond, J., Cunningham, D. & Mehta, J. (1995) Kinetics of paraprotein clearance after autografting for multiple myeloma. Bone Marrow Transplantation, 16, 537-540.
25. World Health Organisation (1987) Handbook for Reporting Results of Cancer Treatment. WHO offset publication (1987) No. 48, Geneva.